

*Supplementary file*

**Table 1. Tuberculosis resistance profile and HIV positive status in the included studies**

Author Year Registry	Arms	Sample size	HIV +ve	TB resistance profile			
				RR	MD R	Pre - XD R	XDR
Gler, 2012, NCT00685360	DLM 100 mg BID	141	1	NA	141	0	0
	DLM 200 mg BID	136	1	NA	136	0	0
	SOC	125	1	NA	125	0	0
Diacon, 2014, NCT00449644	BDQ	66	5	0	39	15	0
	SOC	66	14	0	46	12	0
Dawson, 2015, NCT01498419	Pa 100 mg	60	12	NA	NA	NA	NA
	Pa 200 mg	62	8	NA	NA	NA	NA
	SOC	59	13	NA	NA	NA	NA
	Pa 200 mg (DR-TB)	26	7	NA	26	NA	NA
Pym, 2016, NCT00910871	BDQ	233	9	0	148	44	38
Tsuyuguchi, 2019, NCT02365623	BDQ	6	0	0	6	0	0
Tweed, 2019, NCT02193776	BloodPaZ	59	8	0	0	0	0
	B200PaZ	60	10	0	0	0	0
	SOC	61	10	0	0	0	0
	BPamZ	60	25	38	0	0	0
Vasilyeva, 2019, NCT01464762	BDQ	57	0	0	0	27	30
von Groote-Bidlingmaier, 2019, NCT01424670	DLM	226	12	0	177	39	10
	SOC	101	6	0	79	20	2

Conradie, 2020, NCT02333799	BDQ	109	56	0	38	0	71
Dooley, 2021, NCT02583048	BDQ	28	10	28	0	0	0
	DLM	28	11	28	0	0	0
	BDQ-DLM	28	10	28	0	0	0
Esmail, 2022, NCT02454205	BDQ	49	27	0	49	0	0
	SOC	44	24	0	44	0	0
Fu, 2021, ChiCTR2000032298	BDQ	35	NM	5	6	0	3
	SOC	68	NM	10	28	0	1
Garcia-Prats, 2022, NCT01859923	12-17 years (DLM 100 mg)	7	NM	0	7	0	0
	6-11 years (DLM 50 mg)	6	NM	0	6	0	0
	3-5 years (DLM 25 mg)	12	NM	0	12	0	0
	0-2 years (DLM 5-10 mg)	12	NM	0	12	0	0
Goodall, 2022, ISRCTN18148631	BDQ	196	27	19 6	0	0	0
	SOC	187	15	18 7	0	0	0
	BDQ 6 mo	134	21	13 4	0	0	0
	SOC 6 mo	127	21	12 7	0	0	0
Mok, 2022, NCT02619994	DLM	79	0	0	79	0	0
	SOC	89	0	0	89	0	0
Nyang'wa, 2022, NCT02589782	SOC	152	41	15 0	0	0	0
	BPaL	123	41	12 1	0	0	0

	BPaLM	151	38	14 4	0	0	0
	BPaLC	126	33	12 2	0	0	0
Yao, 2023, ChiCTR1800020391	BDQ	34	0	0	34	0	0
	BDQ	34	0	0	34	0	0
Cevik, 2024, NCT03338621	SOC	153	27	0	0	0	0
	BPaMZ (DS- TB) 4 (m)	150	25	0	0	0	0
	BPaMZ (DS- TB) 6 (m)	152	35	45	99	1	2
<b>Total</b>		<b>4082</b>	<b>604</b>	<b>1348</b>	<b>1507</b>	<b>347</b>	<b>153</b>

B200PaZ: 200 mg BDQ plus pretomanid and pyrazinamide. BDQ: bedaquiline. BID: twice daily. BloadPaZ: BDQ loading dose plus pretomanid and pyrazinamide. BPaL: bedaquiline, pretomanid, and linezolid. BPaLC: bedaquiline, pretomanid, linezolid, and clofazimine; BPaLM: bedaquiline, pretomanid, linezolid and moxifloxacin; BPaMZ: bedaquiline, pretomanid, moxifloxacin and pyrazinamide; DLM: delamanid. DR-TB: drug-resistant tuberculosis. DS-TB: drug-sensitive tuberculosis. m: months. MDR: multidrug resistant. NM: not mentioned. OBR: optimized background regimen. TB: tuberculosis. Pre-XDR: pre-extensively drug resistant. SOC: standard of care. XDR: extensively drug resistant

**Table 2. Quality assessment of randomized control trial studies using the Delphi list. Q1a: Was a method of randomization performed?; Q1b: Was the treatment allocation concealed?; Q2: Were the groups similar at baseline regarding the most important prognostic indicators?; Q3: Were the eligibility criteria specified?; Q4: Was the outcome assessor blinded?; Q5: Was the care provider blinded?; Q6: Was the patient blinded?; Q7: Were point estimates and measures of variability presented for the primary outcome measures?; Q8: Did the analysis include an intention-to-treat analysis?**

Study (years)	Delphi List							
	Q1a	Q1b	Q2	Q3	Q4	Q5	Q6	Q7
Gler (2012)	Yes	Don't know	Yes	Yes	Don't know	Yes	Yes	Yes
Diacon (2014)	Yes	Don't know	Yes	Yes	Don't know	Yes	Yes	Yes
Dawson (2015)	Yes	No	No	Yes	Yes	No	No	Yes
Tweed (2019)	Yes	No	Don't know	Yes	No	No	No	Yes
von Groote-Bidlingmaier (2019)	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes
Dooley (2021)	Yes	No	Yes	Yes	Yes	No	No	Yes
Esmail (2022)	Yes	No	Yes	Yes	No	No	No	Yes
Goodall (2022)	Yes	No	Yes	Yes	Yes	No	No	Yes
Mok (2022)	Yes	No	Don't know	Yes	Yes	No	No	Yes
Yao (2023)	Yes	Yes	Yes	Yes	Don't know	Yes	Yes	Yes
Cevik (2024)	Yes	No	Don't know	Yes	No	No	No	Yes

**Table 3. Newcastle Ottawa Scale quality assessment of non-randomized controlled trial studies**

Study (year)	Selection				Comparability	Outcome
	Representativeness of the sample	Selection of the non-exposed cohort	Ascertainment of the exposure (risk factor)	Demonstration that outcome of interest was not present at start of study	Comparability between groups	Assessment of outcome
Pym (2016)	*	-	*	*	*	*
Tsuyuguchi (2019)	-	-	*	*	-	*
Conradie (2020)	*	-	*	*	*	*
Fu (2021)	*	*	*	*	**	*
Garcia-Prats (2022)	*	-	*	*	**	*